The Most Comprehensive, State-of-the-Art Book on Using Gene and Cell Therapy in Clinical Medicine
Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition presents extensive background and basic information, state-of-the-art technologies, important achievements, and lingering challenges in the fields of gene and cell therapies. The fourth edition of this bestseller continues to provide the most comprehensive coverage of these fields in one volume. Some chapters have expanded introductions, making the book even more suitable for classroom use. This edition also offers more material on the contributors' research efforts as well as current technologies, disease targets, and clinical applications.
Divided into four sections, the book covers:
- Delivery systems and therapeutic strategies
- Other therapeutic strategies, including technologies that knock down gene expression
- Gene expression, regulation, and detection
- Gene and cell therapies, disease targets, clinical trials, and regulatory issues
Accessible to a broad audience, including students, scientists, physicians, and lay people, this book provides readers with up-to-date, interdisciplinary knowledge and tools to tackle the evolving areas of gene therapy, cell therapy, and tissue engineering. From introductory information to state-of-the-art technologies and concepts, the book helps readers understand vector design and construction, delivery systems, therapeutic strategies, gene expression and detection, disease targets, clinical applications and trials, cell-based therapies, novel imaging systems, gene regulation, and regulatory affairs.
About the Author: Nancy Smyth Templeton earned her PhD in molecular biology and biochemistry from Wesleyan University. She underwent postdoctoral training at the National Institutes of Health in the NCI and the NHLBI. She was recently the director of delivery systems at Gradalis/Strike Bio Inc., focusing on targeted delivery of bifunctional shRNA therapeutics to solid tumors by intravenous injections using her robust nanoparticles: bilamellar invaginated vesicles (BIVs). Dr. Templeton has published 62 peer-reviewed papers, presented over 170 seminars, been issued 16 patents, and won several awards.
